AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Introduction
Exploring Exavir Bio's antibodies targeting spike protein epitopes to effectively neutralize armicron variants of COVID-19, with a focus on diminishing viral escape and promising results in combating SARS-CoV-1 and SARS-CoV-2. The CEO highlights the persistent danger of COVID-19 to vulnerable populations despite vaccine availability.